Annual Accounts Receivable
$32.92 M
+$2.49 M+8.19%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual accounts receivable is currently $32.92 million, with the most recent change of +$2.49 million (+8.19%) on 31 December 2023. During the last 3 years, it has fallen by -$23.93 million (-42.10%). LGND annual accounts receivable is now -61.48% below its all-time high of $85.45 million, reached on 31 December 2021.LGND Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$34.32 M
-$3.16 M-8.44%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly accounts receivable is currently $34.32 million, with the most recent change of -$3.16 million (-8.44%) on 30 September 2024. Over the past year, it has dropped by -$1.69 million (-4.68%). LGND quarterly accounts receivable is now -59.84% below its all-time high of $85.45 million, reached on 31 December 2021.LGND Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.2% | -4.7% |
| 3 y3 years | -42.1% | -46.7% |
| 5 y5 years | -41.1% | +56.3% |
LGND Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -61.5% | +8.2% | -59.8% | +22.6% |
| 5 y | 5 years | -61.5% | +8.3% | -59.8% | +56.3% |
| alltime | all time | -61.5% | +5226.4% | -59.8% | >+9999.0% |
Ligand Pharmaceuticals Incorporated Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $34.32 M(-8.4%) |
| June 2024 | - | $37.48 M(+31.8%) |
| Mar 2024 | - | $28.43 M(-13.6%) |
| Dec 2023 | $32.92 M(+8.2%) | $32.92 M(-8.6%) |
| Sept 2023 | - | $36.00 M(+28.6%) |
| June 2023 | - | $27.99 M(-4.1%) |
| Mar 2023 | - | $29.19 M(-4.1%) |
| Dec 2022 | $30.42 M(-64.4%) | $30.42 M(-53.3%) |
| Sept 2022 | - | $65.17 M(+4.6%) |
| June 2022 | - | $62.31 M(+49.1%) |
| Mar 2022 | - | $41.80 M(-51.1%) |
| Dec 2021 | $85.45 M(+50.3%) | $85.45 M(+32.8%) |
| Sept 2021 | - | $64.34 M(+10.6%) |
| June 2021 | - | $58.16 M(+6.8%) |
| Mar 2021 | - | $54.44 M(-4.2%) |
| Dec 2020 | $56.85 M(+87.1%) | $56.85 M(+72.8%) |
| Sept 2020 | - | $32.91 M(-21.4%) |
| June 2020 | - | $41.87 M(+6.0%) |
| Mar 2020 | - | $39.51 M(+30.0%) |
| Dec 2019 | $30.39 M(-45.6%) | $30.39 M(+38.4%) |
| Sept 2019 | - | $21.96 M(+8.4%) |
| June 2019 | - | $20.26 M(-23.9%) |
| Mar 2019 | - | $26.61 M(-52.3%) |
| Dec 2018 | $55.85 M(+118.2%) | $55.85 M(+18.9%) |
| Sept 2018 | - | $46.98 M(+11.8%) |
| June 2018 | - | $42.00 M(+13.2%) |
| Mar 2018 | - | $37.11 M(+45.0%) |
| Dec 2017 | $25.60 M(+74.1%) | $25.60 M(+99.7%) |
| Sept 2017 | - | $12.82 M(-4.8%) |
| June 2017 | - | $13.46 M(+90.8%) |
| Mar 2017 | - | $7.06 M(-52.0%) |
| Dec 2016 | $14.70 M(+138.2%) | $14.70 M(+123.2%) |
| Sept 2016 | - | $6.59 M(-33.9%) |
| June 2016 | - | $9.97 M(-15.4%) |
| Mar 2016 | - | $11.78 M(+90.9%) |
| Dec 2015 | $6.17 M(-51.2%) | $6.17 M(+11.8%) |
| Sept 2015 | - | $5.52 M(-0.3%) |
| June 2015 | - | $5.53 M(-25.5%) |
| Mar 2015 | - | $7.42 M(-41.2%) |
| Dec 2014 | $12.63 M(+468.6%) | $12.63 M(+117.4%) |
| Sept 2014 | - | $5.81 M(+85.5%) |
| June 2014 | - | $3.13 M(-33.0%) |
| Mar 2014 | - | $4.67 M(+110.3%) |
| Dec 2013 | $2.22 M | $2.22 M(-59.7%) |
| Sept 2013 | - | $5.51 M(+687.8%) |
| June 2013 | - | $699.00 K(-84.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $4.62 M(+0.7%) |
| Dec 2012 | $4.59 M(-24.9%) | $4.59 M(+112.7%) |
| Sept 2012 | - | $2.16 M(+164.0%) |
| June 2012 | - | $817.00 K(-59.0%) |
| Mar 2012 | - | $1.99 M(-67.4%) |
| Dec 2011 | $6.11 M(+515.3%) | $6.11 M(+255.4%) |
| Sept 2011 | - | $1.72 M(+65.6%) |
| June 2011 | - | $1.04 M(-24.9%) |
| Mar 2011 | - | $1.38 M(+39.3%) |
| Dec 2010 | $993.00 K(+60.7%) | $993.00 K(+934.4%) |
| Sept 2010 | - | $96.00 K(-99.0%) |
| June 2010 | - | $9.78 M(+3180.9%) |
| Mar 2010 | - | $298.00 K(-51.8%) |
| Dec 2009 | $618.00 K(-94.4%) | $618.00 K(-70.7%) |
| Sept 2009 | - | $2.11 M(+101.0%) |
| June 2009 | - | $1.05 M(-61.3%) |
| Mar 2009 | - | $2.71 M(-75.2%) |
| Dec 2008 | $10.96 M(-4.9%) | $10.96 M(>+9900.0%) |
| Sept 2007 | - | $14.00 K(-72.0%) |
| June 2007 | - | $50.00 K(-96.1%) |
| Mar 2007 | - | $1.27 M(-89.0%) |
| Dec 2006 | $11.52 M(-45.0%) | $11.52 M(+62.8%) |
| Sept 2006 | - | $7.08 M(-62.1%) |
| June 2006 | - | $18.67 M(-6.9%) |
| Mar 2006 | - | $20.05 M(-4.3%) |
| Dec 2005 | $20.95 M(-32.1%) | $20.95 M(-14.0%) |
| Sept 2005 | - | $24.38 M(+16.0%) |
| June 2005 | - | $21.02 M(+14.7%) |
| Mar 2005 | - | $18.32 M(-40.6%) |
| Dec 2004 | $30.85 M(+63.2%) | $30.85 M(+0.9%) |
| Sept 2004 | - | $30.58 M(+70.5%) |
| June 2004 | - | $17.94 M(+26.4%) |
| Mar 2004 | - | $14.19 M(-25.0%) |
| Dec 2003 | $18.90 M(+55.2%) | $18.90 M(+90.5%) |
| Sept 2003 | - | $9.92 M(+29.1%) |
| June 2003 | - | $7.69 M(-55.0%) |
| Mar 2003 | - | $17.09 M(+40.3%) |
| Dec 2002 | $12.18 M(+24.3%) | $12.18 M(+73.9%) |
| Sept 2002 | - | $7.00 M(-48.1%) |
| June 2002 | - | $13.50 M(+78.3%) |
| Mar 2002 | - | $7.57 M(-22.7%) |
| Dec 2001 | $9.80 M(-23.6%) | $9.80 M(+52.3%) |
| Sept 2001 | - | $6.43 M(+24.6%) |
| June 2001 | - | $5.16 M(+5.1%) |
| Mar 2001 | - | $4.91 M(-61.7%) |
| Dec 2000 | $12.82 M | $12.82 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual accounts receivable?
- What is the all time high annual accounts receivable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual accounts receivable?
The current annual accounts receivable of LGND is $32.92 M
What is the all time high annual accounts receivable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual accounts receivable is $85.45 M
What is Ligand Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
Over the past year, LGND annual accounts receivable has changed by +$2.49 M (+8.19%)
What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable?
The current quarterly accounts receivable of LGND is $34.32 M
What is the all time high quarterly accounts receivable for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly accounts receivable is $85.45 M
What is Ligand Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
Over the past year, LGND quarterly accounts receivable has changed by -$1.69 M (-4.68%)